DRUG DISCOVERY

Drug discovery involves identifying and developing new medications through research, screening compounds, understanding disease mechanisms

Tumor-initiating cells, residing within tumor tissue, are the origin of malignant cancer cells, ultimately leading to tumor relapse and fatality. There is a critical necessity to explore pharmaceutical interventions that selectively target these tumor stem cells

The program is dedicated to exploring and uncovering novel nature-inspired molecular conformations to develop targeted treatments for various types of cancers, including their subtypes and metastatic conditions. This includes a focus on addressing previously deemed untreatable cancers by developing strategies to target traditionally “undruggable” molecular pathways (targets like Wnt, Ras, cMyc)

The company’s intellectual property encompasses several primary candidates targeting head and neck cancers, breast cancers, and Mesendron©, representing a novel approach utilizing CAR-t technology for treating solid tumors